Publication & Citation Trends
Publications
0 total
928P Safety and activity of the MET-TKI DO-2 in patients with advanced solid tumors: Phase I study
Cited by 0
Semantic Scholar
EP.12.52 A High-Fat Meal Optimizes the Pharmacokinetic Profile of DO-2, a Novel MET-Kinase Inhibitor for NSCLC
Cited by 0
Semantic Scholar
P3.18.66 Preliminary Safety and PK of the MET-TKI Do-2 in Advanced Solid Tumors With MET Aberrations: Phase I Study
Cited by 0
Semantic Scholar
995P Food for thought: Effect of a high-fat meal on DO-2, a novel MET-kinase inhibitor
Cited by 0
Semantic Scholar
143 (PB131): Preliminary Safety and Pharmacokinetics of the MET-TKI DO-2 in Patients with Advanced Solid Tumors Harboring MET Aberrations: A Phase I Study
Cited by 1
Semantic Scholar
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules
Cited by 25
Semantic Scholar
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study OA
Cited by 21
Semantic Scholar
Research Topics
Cancer therapeutics and mechanisms
(190)
Cancer Treatment and Pharmacology
(188)
Sarcoma Diagnosis and Treatment
(137)
Gastrointestinal Tumor Research and Treatment
(103)
Neutropenia and Cancer Infections
(91)
Affiliations
Université Claude Bernard Lyon 1
University of Pisa
Human Genome Sciences (United States)
Roche (Switzerland)
Uppsala University